Severe radiotherapy-induced extracutaneous toxicity under vemurafenib

European Journal of Dermatology

Volumn 23, Issue 6, 2013, Pages 879-881

  Peuvrel, Lucie ^a   Ruellan, Anne Lise ^a   Thillays, François ^b   Quereux, Gaëlle ^a   Brocard, Anabelle ^a   Saint Jean, Mélanie ^a   Aumont, Maud ^b   Drouet, Franck ^b   Dreno, Brigitte ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Nantes University Hospital ^*  (France)

Author keywords

Anorectitis; BRAF inhibitor; Brain radionecrosis; Melanoma; Radiotherapy; Vemurafenib

Indexed keywords

VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ALOPECIA; ANORECTITIS; ARTHRALGIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; CASE REPORT; COLOSTOMY; DARIER DISEASE; FEMALE; HUMAN; MALE; MELANOMA; MIDDLE AGED; PHOTOSENSITIVITY; RADIATION DERMATITIS; RADIATION INJURY; RADIATION NECROSIS; RADIOSENSITIZATION; SKIN DISEASE; ANAL CANAL; BRAIN; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; NECROSIS; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROCTITIS; RADIATION INJURIES; RADIATION RESPONSE; RADIOSURGERY; RECTAL NEOPLASMS; RECTUM; SECONDARY;

ADULT; ANAL CANAL; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; NECROSIS; NEOPLASMS, SECOND PRIMARY; PROCTITIS; RADIATION INJURIES; RADIOSURGERY; RECTAL NEOPLASMS; RECTUM; SULFONAMIDES;

EID: 84893248463     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2193     Document Type: Article

References (15)

1. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011; 98: 394-9.
2. Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. J Clin Oncol 2013; 31: e220-2.
3. Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and Radiosensitization. JAMA Dermatol 2013; 149: 855-7.
4. Narayana A, Mathew M, Tam M, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113: 411-6.
5. Khan MK, Khan N, Almasan A, Macklis R. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther 2011; 4: 137-48.
6. Suh JH. Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 2010; 362: 1119-27.
7. Di Genesio Pagliuca M, Turri L, Munoz F, et al. Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)". Tumori 2013; 99: 61-7.
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
9. Girard N, Mornex F. [Sorafenib and radiotherapy association for hepatocellular carcinoma]. Cancer Radiother 2011; 15: 77-80.
10. Inoue T, Kinoshita H, Komai Y, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol 2012; 10: 167.
11. Diaz O, Mazeron R, Martin E, Carrie C. [Toxicity of radiation therapy and antiangiogenics combination: a case report]. Cancer Radiother 2009; 13: 205-8.
12. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366: 480-1.
13. Chung EJ, Brown AP, Asano H, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 2009; 15: 3050-7.
14. Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 2011; 71: 6261-9.
15. Yu W, Gu K, Yu Z, et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2013; 329: 109-17.